Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ NAT1 Polyclonal Antibody

Goat Polyclonal Antibody
Supplier: Invitrogen™ PA5143117
This item is not returnable.
View return policy
Description
Additional Information: This antibody is expected to recognize both reported isoforms (NP_000653.3; NP_001153647.1). This antibody is tested in Peptide ELISA: antibody detection limit dilution 1:128,000.
Arylamine N-acetyltransferases (NAT-1 and NAT-2) catalyze N- or O-acetylation of heterocyclic and arylamine substrates in the detoxification of a wide array of drugs. Certain alleles causing high N-acetyltransferase activity have been associated with colon and urinary bladder cancers, as NATs also bioactivate several known carcinogens. Both NAT-1 and NAT-2 are cytoplasmic proteins and play an active role in the detoxification of many arylamine and hydrazine drugs. N-acetylation polymorphism is determined by the level of NAT activity in liver tissues, and has been linked to the action and toxicity of drugs that contain amines. Human NAT-1 is the functional homolog of rodent NAT-2, while human NAT-2 is the functional homolog of rodent NAT-1.
Specifications
| NAT1 | |
| Polyclonal | |
| Unconjugated | |
| NAT1 | |
| AAC1; Arylamide acetylase 1; arylamine N-acetyltransferase 1; AT-1; MNAT; Monomorphic arylamine N-acetyltransferase; N(alpha)-acetyltransferase 15, NatA auxiliary subunit; N-acetyl transferase 1; N-acetyl transferase 1, liver, blood; N-acetyltransferase (arylamine N-acetyltransferase); N-acetyltransferase 1; N-acetyltransferase 1 (arylamine N-acetyltransferase); N-acetyltransferase type 1; Nat; Nat1; NAT-1; NATI | |
| Goat | |
| Ammonium sulfate precipitation | |
| RUO | |
| 9 | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot | |
| 0.5 mg/mL | |
| TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
| P18440 | |
| NAT1 | |
| Peptide with sequence C-NISLQRKLVPKHGDR. | |
| 100 μg | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction